RB
The startup develops peptide therapeutics that enhance immune function and reduce inflammation in severe central nervous diseases by enabling non-covalent attachment of proteins to red blood cells. This technology improves drug circulation and minimizes immunogenicity, thereby optimizing the efficacy of peptide and protein-based treatments.
Updated 2 months ago
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops peptide therapeutics that enhance immune function and reduce inflammation in severe central nervous diseases by enabling non-covalent attachment of proteins to red blood cells. This technology improves drug circulation and minimizes immunogenicity, thereby optimizing the efficacy of peptide and protein-based treatments.